Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07562568 Zeprumetostat Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07562568 clinical trial report covering Zeprumetostat, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07560475 Trastuzumab Rezetecan Advanced HER2-Positive Breast Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07560475 clinical trial report covering Trastuzumab Rezetecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07561645 Obrixtamig Large cell neuroendocrine carcinoma of lung Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07561645 clinical trial report covering Obrixtamig, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07562191 Dimethyltryptamine Suicidal Ideation Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07562191 clinical trial report covering Dimethyltryptamine, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07560826 Methotrexate Osteosarcoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07560826 clinical trial report covering Methotrexate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07563010 Revumenib Adult Acute Myeloblastic Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07563010 clinical trial report covering Revumenib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07564453 Blinatumomab CD19-positive B-cell acute lymphoblastic leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07564453 clinical trial report covering Blinatumomab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07564479 Lipoic acid Nephrotoxicity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07564479 clinical trial report covering Lipoic acid, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07565324 Trastuzumab HER2 Positive Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07565324 clinical trial report covering Trastuzumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07563296 Ketamine Hydrochloride Burns Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07563296 clinical trial report covering Ketamine Hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07565389 Ivonescimab Nasopharyngeal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07565389 clinical trial report covering Ivonescimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07564245 Cannabidiol Neurodevelopmental Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07564245 clinical trial report covering Cannabidiol, Phase 2, endpoints, sponsor, geography, readout timing and development white space.